FUJIFILM Diosynth Biotechnologies News and Resources

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organisation (CDMO), has completed its first expansion at its Hillerød, Denmark site. This project doubles its mammalian cell culture capacity, increasing the number of bioreactors from six to twelve and establishing

FUJIFILM Diosynth Biotechnologies, a global CDMO for biologics and advanced therapies, has completed the expansion of its cell therapy manufacturing facility in Thousand Oaks, California. The investment includes two new cGMP production suites and enhanced development labs, significantly increasing capacity

FUJIFILM Diosynth Biotechnologies has completed the initial phase of its production capacity expansion at its Hillerød, Denmark site. This expansion adds six 20,000 L mammalian cell bioreactors, doubling the site’s capacity and bringing its total to 12 bioreactors, in a

FUJIFILM Diosynth Biotechnologies has entered a multi-year agreement with TG Therapeutics to manufacture BRIUMVI (ublitiximab-xiiy), a U.S. FDA-approved treatment for relapsing multiple sclerosis (RMS). As part of the agreement, FUJIFILM Diosynth will provide secondary manufacturing from its upcoming biopharmaceutical facility

Jacobs has been chosen by FUJIFILM Diosynth Biotechnologies to manage a $1.2 billion expansion of their cell culture contract manufacturing site in Holly Springs, North Carolina. This project builds on the initial construction phase that began in 2021, with Jacobs